Spots Global Cancer Trial Database for hematologic disease
Every month we try and update this database with for hematologic disease cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia | NCT02952508 | Waldenstrom Mac... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... Mantle Cell Lym... Diffuse Large B... Central Nervous... | Iopofosine I 13... Iopofosine I 13... Iopofosine I 13... | 18 Years - | Cellectar Biosciences, Inc. | |
| Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma | NCT00113204 | Multiple Myelom... | IPI-504 | 18 Years - | Infinity Pharmaceuticals, Inc. | |
| Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma | NCT00113204 | Multiple Myelom... | IPI-504 | 18 Years - | Infinity Pharmaceuticals, Inc. | |
| Study of Oral LOXO-338 in Patients With Advanced Blood Cancers | NCT05024045 | Leukemia, Lymph... Lymphoma, B-cel... Lymphoma, Non-H... Multiple Myelom... B-cell Lymphoma Waldenstrom Mac... Lymphoma, Mantl... | LOXO-338 Pirtobrutinib | 18 Years - | Eli Lilly and Company | |
| Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia | NCT02952508 | Waldenstrom Mac... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... Mantle Cell Lym... Diffuse Large B... Central Nervous... | Iopofosine I 13... Iopofosine I 13... Iopofosine I 13... | 18 Years - | Cellectar Biosciences, Inc. | |
| Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer | NCT05172700 | Leukemia, Lymph... Lymphoma, Lymph... Lymphoma, Mantl... Waldenstrom Mac... Ritcher's Trans... | Pirtobrutinib | 18 Years - | Eli Lilly and Company | |
| Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) | NCT01435720 | Multiple Myelom... Multiple Myelom... Mantle Cell Lym... Diffuse Large B... Other B Cell Ly... Plasma Cell Leu... | SNS01-T SNS01-T SNS01-T SNS01-T | 18 Years - | Senesco Technologies, Inc. | |
| Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia | NCT00113802 | Waldenstrom Mac... | Epratuzumab (hL... | 18 Years - | Gilead Sciences | |
| A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT05023980 | Chronic Lymphoc... Small Lymphocyt... | Pirtobrutinib Bendamustine Rituximab | 18 Years - | Eli Lilly and Company | |
| Safety of Catheter Lock With or Without Heparin in Implanted Central Venous Catheters | NCT00994136 | Oncology, Medic... Hematologic Dis... | normal saline | 1 Year - | Universitaire Ziekenhuizen KU Leuven | |
| Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma | NCT00113204 | Multiple Myelom... | IPI-504 | 18 Years - | Infinity Pharmaceuticals, Inc. | |
| A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | NCT04965493 | Chronic Lymphoc... Small Lymphocyt... | Pirtobrutinib Venetoclax Rituximab | 18 Years - | Eli Lilly and Company | |
| Safety of Catheter Lock With or Without Heparin in Implanted Central Venous Catheters | NCT00994136 | Oncology, Medic... Hematologic Dis... | normal saline | 1 Year - | Universitaire Ziekenhuizen KU Leuven | |
| Functional Evaluation of Two Types of Totally Implanted Venous Ports | NCT00484848 | Hematologic Dis... | Vortex port and... | 18 Years - | Universitaire Ziekenhuizen KU Leuven | |
| A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT05254743 | Chronic Lymphoc... Leukemia, Lymph... Leukemia, B-cel... Small Lymphocyt... | Pirtobrutinib Ibrutinib | 18 Years - | Eli Lilly and Company | |
| A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT05023980 | Chronic Lymphoc... Small Lymphocyt... | Pirtobrutinib Bendamustine Rituximab | 18 Years - | Eli Lilly and Company |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
